DIABETES MELLITUS: Cardiovascular and renal benefits of SGLT2 inhibition: insights from CANVAS

    loading  Checking for direct PDF access through Ovid

Abstract

Inhibitors of renal sodium/glucose cotransporter 2 (SGLT2) are new anti-hyperglycaemic drugs that reduce proximal tubular glucose and sodium reabsorption. The Canagliflozin Cardiovascular Assessment Study (CANVAS) Program is the second major trial to demonstrate beneficial effects of SGLT2 inhibitors on the kidney and cardiovascular system in patients with type 2 diabetes mellitus.

Related Topics

    loading  Loading Related Articles